Jeevan Scientific Technology Ltd
Jeevan Scientific Technology Limited established in 1999, is a clinical research organization with a focus on Pharmacovigilance (PV- tracking and reporting adverse drug reactions after drug launch) & clinical trial business (CT). Its target market is small and medium-sized pharma companies for PV & for CT it focuses on both domestic & international markets. [1]
- Market Cap ₹ 78.7 Cr.
- Current Price ₹ 50.8
- High / Low ₹ 70.0 / 42.2
- Stock P/E 1,311
- Book Value ₹ 32.4
- Dividend Yield 0.00 %
- ROCE -1.03 %
- ROE -2.69 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.70% over past five years.
- Promoter holding is low: 38.7%
- Company has a low return on equity of 3.50% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 90.6 to 113 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
17.39 | 18.21 | 20.39 | 26.13 | 23.94 | 46.90 | 67.79 | 36.18 | 39.65 | 45.48 | |
15.59 | 15.01 | 16.96 | 20.27 | 30.02 | 29.41 | 51.02 | 34.82 | 35.01 | 37.76 | |
Operating Profit | 1.80 | 3.20 | 3.43 | 5.86 | -6.08 | 17.49 | 16.77 | 1.36 | 4.64 | 7.72 |
OPM % | 10.35% | 17.57% | 16.82% | 22.43% | -25.40% | 37.29% | 24.74% | 3.76% | 11.70% | 16.97% |
0.37 | 0.58 | 0.92 | 1.00 | 2.50 | 2.39 | 5.91 | 1.07 | 0.67 | 0.39 | |
Interest | 1.28 | 1.54 | 1.87 | 2.36 | 3.04 | 2.26 | 0.96 | 1.04 | 0.98 | 1.26 |
Depreciation | 0.68 | 1.23 | 2.12 | 3.13 | 3.92 | 3.97 | 3.69 | 5.07 | 5.93 | 6.04 |
Profit before tax | 0.21 | 1.01 | 0.36 | 1.37 | -10.54 | 13.65 | 18.03 | -3.68 | -1.60 | 0.81 |
Tax % | 104.76% | 10.89% | 69.44% | 18.25% | -18.60% | 13.99% | 33.78% | -16.58% | -17.50% | |
-0.01 | 0.90 | 0.11 | 1.11 | -8.59 | 11.74 | 11.94 | -3.07 | -1.33 | 0.06 | |
EPS in Rs | -0.02 | 0.97 | 0.10 | 0.73 | -5.61 | 7.67 | 7.80 | -1.97 | -0.84 | 0.08 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.52% | 15.38% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | -5% |
TTM: | 25% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 103% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | -20% |
1 Year: | -11% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 4% |
Last Year: | -3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.04 | 9.28 | 11.46 | 15.30 | 15.30 | 15.30 | 15.30 | 15.48 | 15.48 | 15.48 |
Reserves | -2.27 | 7.60 | 7.42 | 16.53 | 7.92 | 19.72 | 35.28 | 32.71 | 32.95 | 34.62 |
11.08 | 8.45 | 18.78 | 18.15 | 17.95 | 10.34 | 12.55 | 10.10 | 13.41 | 16.25 | |
5.56 | 5.56 | 11.72 | 11.32 | 12.70 | 20.62 | 14.75 | 7.63 | 6.03 | 6.79 | |
Total Liabilities | 20.41 | 30.89 | 49.38 | 61.30 | 53.87 | 65.98 | 77.88 | 65.92 | 67.87 | 73.14 |
8.67 | 16.35 | 28.17 | 32.59 | 30.54 | 27.38 | 19.07 | 24.97 | 26.66 | 30.44 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.90 | 2.81 | 3.49 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
11.74 | 14.54 | 21.21 | 28.71 | 23.33 | 38.60 | 58.81 | 39.05 | 38.40 | 39.21 | |
Total Assets | 20.41 | 30.89 | 49.38 | 61.30 | 53.87 | 65.98 | 77.88 | 65.92 | 67.87 | 73.14 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
3.55 | -5.62 | 5.65 | 4.04 | -0.01 | 4.95 | 19.56 | -6.41 | 2.89 | |
-3.63 | -8.90 | -14.35 | -7.87 | -1.90 | -0.80 | -1.20 | -6.93 | -11.53 | |
0.23 | 14.57 | 9.86 | 6.08 | 0.44 | -0.13 | 5.67 | -9.54 | 2.35 | |
Net Cash Flow | 0.15 | 0.05 | 1.17 | 2.25 | -1.47 | 4.02 | 24.03 | -22.88 | -6.29 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 151.96 | 227.10 | 291.79 | 205.20 | 104.29 | 112.46 | 40.97 | 117.83 | 113.14 |
Inventory Days | 72.11 | 105.50 | 104.15 | ||||||
Days Payable | 98.78 | 322.56 | 205.43 | ||||||
Cash Conversion Cycle | 151.96 | 227.10 | 291.79 | 205.20 | 104.29 | 112.46 | 14.30 | -99.23 | 11.85 |
Working Capital Days | 103.48 | 139.91 | 161.47 | 98.34 | 11.59 | 57.43 | 54.97 | 154.05 | 172.24 |
ROCE % | 12.69% | 7.08% | 8.51% | -16.39% | 36.77% | 27.58% | -4.34% | -1.03% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Copy of Newspaper Cuttings of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2024.
-
Announcement under Regulation 30 (LODR)-Change in Management
8 Nov - Approval of financial results and key management changes.
- Un Audited Financial Results ( Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024 8 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 08.11.2024
8 Nov - Approval of financial results and key management changes.
-
Board Meeting Intimation for The Meeting To Be Held On 08.11.2024
2 Nov - Board meeting scheduled for November 8, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Contract Research Organisation[1]
The company forayed into the Clinical research space in 2014 with the aim of providing quality and cost-effective services to Pharma and biotech companies across the globe and now primarily focuses on specialty drugs like biosimilars and is building expertise on the same.